RCRené Chapot

René Chapot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


René Chapot has a total of 537 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Improvement, No Improvement, and Worsening at 24 Hours Following Reperfusion in Patients With Stroke due to Large-Vessel Occlusion

    by Umberto Pensato, Thalia S. Field, Brian van Adel, Ruchir Shah, Jason W. Tarpley, Hana Choe, Nima Kashani, Mohammed Almekhlafi, Raul G. Nogueira, Ryan A. McTaggart, et al.

    BACKGROUND: Restoring blood flow to ischemic tissue is the cornerstone of acute stroke therapy and is usually beneficial. However, when reperfusion is achieved for severely injured tissue, it is often futile and may occasionally cause harm. We aim to determine the prevalence and variables associated with clinical no improvement or acute worsening at 24 hours despite reperfusion in patients with large-vessel occlusion stroke treated with endovascular thrombectomy. METHODS: Data are from ESCAPE-NA1 (Safety and Efficacy of Nerinetide [NA-1] in Subjects Undergoing Endovascular Thrombectomy for Stroke), a randomized trial of nerinetide in patients with acute large-vessel occlusion stroke undergoing endovascular thrombectomy. Patients with unsuccessful recanalization (expanded Thrombolysis in Cerebral Infarction <2b), infarcts in new vascular territories, vessel perforation, or remote parenchymal hemorrhage were excluded. Clinical outcomes after reperfusion were classified by 24-hour National Institutes of Health Stroke Scale changes compared with baseline: improvement (≥4-point improvement), no improvement (±3-point from baseline), and worsening (≥4-point worsening). Baseline variables associated with worsening were identified using logistic regression. In the computed tomography perfusion subgroup, prevalence of parenchymal hemorrhage (any parenchymal hematoma) and infarct progression (final infarct volume exceeding the initial hypoperfused region) were evaluated. RESULTS: A total of 833 patients were included (median age, 70.9 years [interquartile range, 60.7–79.4]; 51.4% men). After reperfusion, 669 (80.3%) patients improved, 135 (16.2%) showed no improvement, and 29 (3.5%) worsened. Independent predictors of worsening were longer onset-to-reperfusion time (adjusted odds ratio, 1.02 [95% CI, 1.00–1.04] per 10-minute increase) and greater degree of sedation (adjusted odds ratio, 1.78 [95% CI, 1.29–2.46] per category of none, conscious sedation, and general anesthesia). In the computed tomography perfusion subgroup (n=414), among patients with worsening after reperfusion, parenchymal hemorrhage was seen in 5 patients (31.3%) and infarct progression in 4 patients (25%). CONCLUSIONS: Clinical worsening in the acute period (ie, early neurological deterioration) despite reperfusion and the absence of procedure-related complications was rare in this selected large-vessel occlusion stroke cohort (3.5%). Factors associated with worsening after reperfusion were a longer time from symptom onset-to-reperfusion and a higher degree of sedation.

  • Open Access

    Predictors of treatment failure after middle meningeal artery embolization for chronic subdural hematoma: a German nationwide multicenter study

    by Philip Heesen, Ansgar Berlis, Mahmoud Zaki, Christoph Johannes Maurer, Christina Onyinzo, Fee C Keil, Leonhard Mann, Christophe T Arendt, Marius K Hartmann, Steffen Reißberg, et al.

    Introduction Embolization of the middle meningeal artery (EMMA) is an emerging treatment for chronic subdural hematoma (cSDH), yet predictors of treatment failure (TF) remain incompletely characterized. We aimed to identify independent predictors of TF after EMMA for cSDH in a large German nationwide multicenter cohort. Methods In this secondary analysis of a retrospective multicenter study, 569 consecutive patients who underwent 718 EMMA procedures for cSDH across 30 German neurovascular centers (January 2014 to December 2023) were analyzed. TF was defined as residual cSDH >10 mm, hematoma progression, or requirement of rescue surgery. Rescue surgery alone, as well as absolute and relative size reduction, were secondary endpoints. The unit of analysis was the individual embolization procedure. Mixed-effects multivariable logistic regression was performed to identify independent predictors of TF. Results In multivariable analysis, cSDH thickness (adjusted OR (aOR) 1.09, 95% CI 1.05 to 1.13, PConclusion Antithrombotic medication use and greater hematoma thickness were independent predictors of TF after EMMA. These factors may guide individualized treatment selection.

  • Open Access

    Recanalisation quality, not first-pass effect, drives outcomes in paediatric mechanical thrombectomy: a multicentre prospective study

    by Adam A Dmytriw, Iman Kiani, Kartik Bhatia, Todd Abruzzo, Lisa Pabst, Stuart Fraser, Melissa G Chung, Warren Lo, Ahmed Othmann, Sebastian Steinmetz, et al.

    Introduction: In adult endovascular thrombectomy (EVT), first-pass success is associated with better outcomes, but whether this “first-pass effect” also holds true in childhood stroke remains unknown. We investigated the association of thrombectomy pass counts with 90-day outcomes after paediatric EVT. Patients and methods: We analysed prospectively collected data from the international Save ChildS Pro registry (ages 0–17 years). All EVT-treated patients were included irrespective of the reperfusion grade achieved. Successful reperfusion was defined as expanded thrombolysis in cerebral infarction (eTICI) ≥ 2b and complete/near-complete reperfusion as eTICI 2c–3. The primary outcome was ordinal 90-day mRS in a proportional odds model. Single-pass and multiple-pass patients were then compared with each other within the subgroup achieving eTICI 2c–3. Logistic regression for mRS > 2 was fitted with pass count and eTICI grade as covariates. Results: Of 103 patients (median age 11 years [IQR 6–15]; 55/102 [53.9%] male), median passes were 2 (IQR 1–3); 39 (37.9%) had 1 pass, 61 (59.2%) more than 1 and 3 (2.9%) recanalised without a thrombectomy pass. Multiple passes were associated with lower eTICI 2c–3 rates (30.0% vs 82.1%; P < .001), and worse 90-day mRS (common odds ratio 3.47; 95% CI, 1.63–7.38; P = .001). However, among patients achieving eTICI 2c–3 (n = 50), we detected no difference by pass count (mRS 0–2: 93.8% vs 94.4%; risk difference − 0.6%, 95% CI, −15% to +20%; P = 1.000). After accounting for eTICI, pass count was not independently associated with mRS > 2, while eTICI remained significant. Conclusions: In this analysis of the first-pass effect in paediatric thrombectomy, multiple passes were associated with worse functional outcomes, but this effect appeared to be largely mediated through recanalisation quality. Subgroup analyses were underpowered to exclude a clinically relevant residual effect of pass count, and these findings should be considered hypothesis-generating.

  • Open Access

    Diving MCA and First-Pass Effect: A Subgroup Analysis From the ARISE II Study

    by Yazan Ashouri, Mohammad AlMajali, Amit Chaudhari, Tommy Andersson, Jeffrey L. Saver, Alex Bou Chebl, Saif Bushnaq, Nicholas Liaw, Hormozd Bozorgchami, Marc Ribo, et al.

    BACKGROUND: The impact of internal carotid artery tortuosity on achieving first-pass effect in mechanical thrombectomy has been described; however, middle cerebral artery (MCA) tortuosity remains understudied. We investigated the association of MCA tortuosity with radiographic and functional outcome using quantitative and qualitative measures. METHODS: The ARISE II study (Analysis of Revascularization in Ischemic Stroke With EmboTrap) was used to identify patients with anterior circulation stroke. MCA tortuosity was calculated using the Inflection Count Metric by 2 readers blinded to the angiographic/clinical outcomes. The total cohort was trichotomized into 3 groups (A, B, and C) based on M1 tortuosity tertiles, with group A representing the lowest tertile and group C representing the highest tertile. The primary efficacy end point was the achievement of first-pass expanded Thrombolysis in Cerebral Ischemia reperfusion ≥2c. A good functional outcome was defined as a 90-day modified Rankin Scale score of 0 to 2. Baseline and procedural data were compared between groups. RESULTS: A total of 168 patients with M1 or M2 occlusion and measurable MCA tortuosity were identified. Patients in group C were more likely to have renal disease and hyperlipidemia, whereas patients in group A were more likely to have hypertension ( P P =0.024). The rate of final expanded Thrombolysis in Cerebral Ischemia reperfusion ≥2c was higher in group A (87.5%) versus in groups B and C (77.8% and 66%, respectively; P =0.026); achieving modified Rankin Scale score of 0 to 2 was more likely in group A (77.8%) versus in groups B and C (74.5% and 52.7%, respectively; P =0.008). There were no differences in distal emboli or symptomatic intracranial hemorrhage. First-pass effect and angiographic outcomes were consistent with standard angle of curvature tortuosity. CONCLUSIONS: Patients with higher MCA tortuosity were less likely to achieve first-pass effect, successful reperfusion, and good functional outcome at 90 days postmechanical thrombectomy for acute ischemic stroke. REGISTRATION: URL: http://clinicaltrials.gov ; Unique identifier: NCT02488915.

  • Functional Outcomes and Safety of Endovascular Thrombectomy in Pediatric Acute Ischemic Stroke With Cardiac Abnormalities

    by Adam A. Dmytriw, Iman Kiani, Alireza Kooshki, Kartik D. Bhatia, Todd Abruzzo, Lisa Pabst, Stuart Fraser, Melissa Chung, Warren D. Lo, Ahmed Othmann, et al.

    Background and ObjectivesCardiac abnormalities are among the most common and complex risk factors of pediatric acute ischemic stroke (AIS). Although endovascular treatment (EVT) is increasingly use...

  • Open Access

    Stent-assisted coiling with LVIS Evo and HydroCoil embolic system: 1-year results of the SEALANT study

    by Jonathan Downer, Omer F Eker, Roberto Riva, Ansgar Berlis, Antonio Pitrone, Paul Stracke, Illario Tancredi, Charbel Mounayer, Chrysanthi Papagiannaki, Arun Chandran, et al.

    Background: More high-quality evidence for stent-assisted coiling (SAC) of cerebral aneurysms is needed. Randomized controlled trials have shown lower recurrence with the HydroCoil Embolic System (HES) compared with bare platinum coils, and self-adjudicated LVIS Evo SAC studies have demonstrated favorable safety and technical success. The objective of the SEALANT study is to investigate the safety and effectiveness of this device combination. Methods: SEALANT is an open-label, prospective, single-arm, multicenter study including patients with aneurysms up to a maximum size of 12 mm. The primary effectiveness endpoint was complete occlusion on digital subtraction angiography (DSA), and the primary safety endpoint was major ipsilateral stroke or neurological death. Adverse events and imaging were independently adjudicated. Results: 206 patients were enrolled; 193 had follow-up imaging for outcome assessment; and 164 satisfied all criteria, were treated with both study devices (including ≥90% HES), and had DSA follow-up. The participants’ mean age was 56.8±11.6 years; 65% were female. Of 212 aneurysms, 86.3% were bifurcation and 13.2% sidewall; 25.0% were previously treated and 17.9% previously ruptured; 89.6% were anterior circulation, 34.0% at the anterior communicating artery, and 30.7% at the middle cerebral artery; and 84.9% were wide-necked (neck ≥4 mm or dome/neck ratio <2). The primary effectiveness endpoint of complete occlusion was achieved in 82.1% (95% CI 76.4% to 87.9%) of aneurysms. 2.4% (95% CI 0.3% to 4.5%) of patients met the primary safety endpoint of major ipsilateral stroke or neurological death. The primary safety endpoint was significantly associated with baseline modified Rankin Scale and history of previous stroke. Conclusion: 1-year SEALANT results confirm the safety and effectiveness of SAC using LVIS Evo and HES. Trial registration number: NCT04999423 .

  • Top Cited Papers

    Acute Management of Medium Vessel Occlusion Stroke: New Evidence and a Path Forward

    by William K. Diprose, Umberto Pensato, Mohammed Almekhlafi, Marios-Nikos Psychogios, Urs Fischer, Frédéric Clarençon, René Chapot, Wei Hu, Thanh N. Nguyen, Shinichi Yoshimura, et al.

    Acute stroke due to medium vessel occlusion (MeVO) accounts for 25% to 40% of all acute ischemic stroke cases and is associated with substantial morbidity despite current best medical management. This motivated several recently published and ongoing trials that investigate(d) the benefit of endovascular thrombectomy (EVT) for MeVO stroke. Two of these trials have been published, an interim analysis of a third has been presented, and a fourth will be presented soon. The available trial results suggest no difference in outcomes between EVT and best medical management, and a possibility of harm with EVT. Preliminary post hoc analyses have however identified promising patient subgroups that may derive benefit from EVT. Improving EVT tools and techniques, together with adjunctive treatments, may further increase the technical efficacy of MeVO EVT. This review summarizes clinical and imaging features of MeVO stroke, reviews current evidence for medical and endovascular treatment, discusses recent MeVO EVT trial results, and outlines possible pathways forward for future MeVO trials.